ELIGARD® (Leuprolide Acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer
June 07, 2019 08:55 ET
|
TOLMAR Pharmaceuticals, Inc.
CHICAGO, June 07, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals Inc., a fully integrated specialty pharmaceutical company, today announced new formulary placement for ELIGARD® with Rite-Aid’s...